Do we need new therapeutic strategies for depression?

Psychiatria Danubina

Volumn 23, Issue 3, 2011, Pages 300-301

  Mihaljević Peleš, Alma ^a   Šagud, Marina ^a   Janović, Maja Bajs ^a   Mikulić, Suzan Kudlek ^a   Jevtović, Saša ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

CLINICAL ASSESSMENT; CONFERENCE PAPER; DEPRESSION; HUMAN; NEUROTRANSMISSION; PATHOGENESIS; PATHOPHYSIOLOGY; PHARMACOGENOMICS;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE;

EID: 80054119442     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Crisafulli C, Fabbri C, Porcelli S, Drago A, Spina E, De Ronchi D, Serretti A. Pharmacogenetics of antidepressants. Frontiers in Pharmacology Pharmacogenetics and Pharmacogenomics. 2011.
2. Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, Russell JM. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002; 63:963-71. (Pubitemid 35388053)
3. Fleck MP, Berlim MT, Lafer B, Sougey EB, Del Porto JA, Brasil MA, Juruen MF, Hetem LA. Review of the guidelines of the Brazilian Medical Association for the treatment of depression (Full version). Rev. Bras. Psiquiatr. 2009; vol.31 supl.1.
4. Fornaro M and Giosuè P. Current Nosology of Treatment Resistant Depression: A Controversy Resistant to Revision. Clinical Practice Sc Epidemiology in Mental Health, 2010, 6:20-24.
5. Gibson TB, Jing Y, Smith Carls G, Kim E, Bagalman JE, Burton WN, Tran QV, Pikalov A, Goetzel RZ. Cost burden of treatment resistance in patients with depression. Am J Manag Care. 2010; 16:370-7.
6. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS; National Co morbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Co morbidity Survey Replication (NCS-R). JAMA. 2003; 289:3095-105. (Pubitemid 37432885)
7. Marks DM, Pae Ch-U and Patkar AA. Triple Reuptake Inhibitors: The Next Generation of Antidepressants. Curr Neuropharmacol. 2008; 6:338-343.
8. Mueller TI, Leon A C, Keller MB, Solomon DA, Endicott J, Coryell W, Warshaw M, Maser JD., Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999; 156:1000-6. (Pubitemid 29302790)
9. Nemeroff CB. Prevalence and management of treatmentresistant depression. J Clin Psychiatry 2007, 68 (Suppl 8): 17-25.
10. Lépine JP, Briley M. Neuropsychiatr Dis Treat. 2011; 7 (Suppl 1):3-7. Epub 2011 May 31. The increasing burden of depression.
11. Papakostas GI, Petersen T, Pava J, Massen E, Worthington JJ 3rd, Alpert JE, Fava M, Nierenberg AA. Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome. J Nerv Ment Dis. 2003; 191:444-9. (Pubitemid 36944625)
12. Posternak MA, Solomon DA, Leon AC, Mueller TI, Shea MT, Endicott J, Keller MB. The naturalistic course of unipolar major depression in the absence of somatic therapy. J Nerv Ment Dis. 2006; 194:324-9. (Pubitemid 43841196)
13. Ronalds C, Creed F, Stone K, Webb S, Tomenson B. Outcome of anxiety and depressive disorders in primary care. Br J Psychiatr. 1997; 171:427-33. (Pubitemid 27475839)
14. Rost K, Zhang M, Fortney J, Smith J, Coyne J, Smith GR Jr. Persistently poor outcomes of undetected major depression in primary care. Gen Hosp Psychiatry. 1998; 20:12-20. (Pubitemid 28109984)
15. WHO. The World Health Report 2001 - Mental Health: New Understanding, New Hope.
16. World Health Organization. Geneva: World Health Organization; 2001.